Cheryl Pegus - 02 Mar 2026 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: Director
Signature: /s/ Susan Thompson, Attorney-in-Fact
Issuer symbol: BSX
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 19:35:31 UTC
Previous filing: 06 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pegus Cheryl	Director	300 BOSTON SCIENTIFIC WAY, MARLBOROUGH	/s/ Susan Thompson, Attorney-in-Fact	04 Mar 2026	0001572448

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Deferred Stock Units	Award		+24	+0.41%	$0.000000^*	5,917	02 Mar 2026	Common Stock	24		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2	Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

Content

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.